DE602005006757D1 - Als muscarinrezeptorantagonisten geeignete biphenylverbindungen - Google Patents
Als muscarinrezeptorantagonisten geeignete biphenylverbindungenInfo
- Publication number
- DE602005006757D1 DE602005006757D1 DE602005006757T DE602005006757T DE602005006757D1 DE 602005006757 D1 DE602005006757 D1 DE 602005006757D1 DE 602005006757 T DE602005006757 T DE 602005006757T DE 602005006757 T DE602005006757 T DE 602005006757T DE 602005006757 D1 DE602005006757 D1 DE 602005006757D1
- Authority
- DE
- Germany
- Prior art keywords
- receptor antagonists
- compounds suitable
- biphenyl compounds
- muscarin receptor
- muscarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55244304P | 2004-03-11 | 2004-03-11 | |
| PCT/US2005/007988 WO2005087738A1 (en) | 2004-03-11 | 2005-03-10 | Biphenyl compounds useful as muscarinic receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005006757D1 true DE602005006757D1 (de) | 2008-06-26 |
Family
ID=34963910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005006757T Expired - Lifetime DE602005006757D1 (de) | 2004-03-11 | 2005-03-10 | Als muscarinrezeptorantagonisten geeignete biphenylverbindungen |
| DE602005021258T Expired - Lifetime DE602005021258D1 (de) | 2004-03-11 | 2005-03-10 | Biphenylverbindungen geeignet für die Synthese von Muscarinrezeptorantagonisten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005021258T Expired - Lifetime DE602005021258D1 (de) | 2004-03-11 | 2005-03-10 | Biphenylverbindungen geeignet für die Synthese von Muscarinrezeptorantagonisten |
Country Status (27)
| Country | Link |
|---|---|
| US (22) | US7288657B2 (de) |
| EP (2) | EP1930323B1 (de) |
| JP (1) | JP4837653B2 (de) |
| KR (1) | KR101174740B1 (de) |
| CN (1) | CN1930125B (de) |
| AR (2) | AR048032A1 (de) |
| AT (2) | ATE467617T1 (de) |
| AU (1) | AU2005222411B2 (de) |
| BR (1) | BRPI0508622B8 (de) |
| CA (1) | CA2557479C (de) |
| CY (1) | CY1109015T1 (de) |
| DE (2) | DE602005006757D1 (de) |
| DK (1) | DK1723114T3 (de) |
| ES (2) | ES2306125T3 (de) |
| HR (1) | HRP20080301T3 (de) |
| IL (1) | IL177359A (de) |
| MA (1) | MA28524B1 (de) |
| MY (1) | MY144482A (de) |
| NO (1) | NO338941B1 (de) |
| NZ (1) | NZ549472A (de) |
| PL (1) | PL1723114T3 (de) |
| PT (1) | PT1723114E (de) |
| RU (1) | RU2366656C2 (de) |
| SI (1) | SI1723114T1 (de) |
| TW (1) | TWI341836B (de) |
| WO (1) | WO2005087738A1 (de) |
| ZA (1) | ZA200607099B (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1723112A1 (de) * | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Als antagonisten für den muscarinrezeptor geeignete biphenylverbindungen |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1723113A1 (de) * | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen |
| TW200538095A (en) * | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2007528416A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス, インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物 |
| WO2005087737A1 (en) | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2007528412A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス, インコーポレーテッド | ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物 |
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| TW200714587A (en) * | 2005-03-10 | 2007-04-16 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2008537931A (ja) * | 2005-03-10 | 2008-10-02 | セラヴァンス, インコーポレーテッド | ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物 |
| US7659403B2 (en) * | 2005-03-10 | 2010-02-09 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2008533028A (ja) * | 2005-03-10 | 2008-08-21 | セラヴァンス, インコーポレーテッド | ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物 |
| EP1866284A1 (de) * | 2005-03-10 | 2007-12-19 | Theravance, Inc. | Biphenylverbindungen als muskarinrezeptorantagonisten |
| TWI372749B (en) | 2005-03-10 | 2012-09-21 | Theravance Inc | Crystalline forms of a biphenyl compound |
| US7728144B2 (en) | 2005-06-13 | 2010-06-01 | Theravance, Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| PL2599778T3 (pl) | 2009-04-23 | 2018-01-31 | Theravance Respiratory Co Llc | Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2 |
| BR112012000890A2 (pt) | 2009-07-15 | 2017-10-31 | Theravance Inc | formas de base livre cristalina de um composto bifenil |
| JP5959117B2 (ja) | 2010-07-13 | 2016-08-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ビフェニル−2−イルカルバミン酸を調製するためのプロセス |
| US10092552B2 (en) * | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9679336B2 (en) * | 2011-10-19 | 2017-06-13 | Facebook, Inc. | Social ad hoc networking protocol and presentation layer |
| US12226407B2 (en) | 2012-07-24 | 2025-02-18 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CN107074816B (zh) * | 2015-03-27 | 2020-07-17 | 四川海思科制药有限公司 | 一种杂环衍生物及其制备方法和在医药上的用途 |
| WO2017054702A1 (zh) * | 2015-09-28 | 2017-04-06 | 四川海思科制药有限公司 | 一种联苯衍生物及其制备方法和在医药上的用途 |
| WO2017063564A1 (zh) * | 2015-10-13 | 2017-04-20 | 四川海思科制药有限公司 | 一种八氢环戊二烯并[c]吡咯衍生物及其制备方法和在医药上的用途 |
| WO2020047225A1 (en) | 2018-08-30 | 2020-03-05 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
| US11591323B2 (en) * | 2019-03-06 | 2023-02-28 | Barry university | Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof |
| CN110526859B (zh) * | 2019-08-07 | 2021-03-12 | 山东百诺医药股份有限公司 | 一种瑞维那新中间体及其制备方法和瑞维那新的制备方法 |
| CN112694434B (zh) * | 2020-12-29 | 2023-06-16 | 浙江和泽医药科技股份有限公司 | 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法 |
| WO2023017404A1 (en) * | 2021-08-13 | 2023-02-16 | Begum Dr M Sasthaa | A device, a compound, for inhalation of an anti-viral agent |
| WO2023104920A1 (en) | 2021-12-09 | 2023-06-15 | Medichem, S.A. | Crystalline acetone solvate of revefenacin |
| CN116496206A (zh) * | 2023-04-21 | 2023-07-28 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种雷芬那辛杂质ii及其制备方法 |
| CN116640088A (zh) * | 2023-05-29 | 2023-08-25 | 新领先(重庆)医药科技有限公司 | 一种高纯度雷芬那辛的制备方法 |
| CN117263848A (zh) * | 2023-09-19 | 2023-12-22 | 山东京卫制药有限公司 | 一种雷芬那辛的吸入喷雾剂 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US747952A (en) * | 1903-03-02 | 1903-12-29 | Harry Cauley Dillon | Ironing-board. |
| BR8007911A (pt) | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| SE8603252L (sv) | 1985-07-30 | 1987-01-31 | Glaxo Group Ltd | Anordning for att tillfora lekemedel till patienter |
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| AU2178392A (en) | 1991-06-12 | 1993-01-12 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| US5337740A (en) | 1991-08-01 | 1994-08-16 | New England Pharmaceuticals, Inc. | Inhalation devices |
| US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| PT613371E (pt) | 1991-12-18 | 2002-07-31 | Astrazeneca Ab | Nova combinacao de formoterol e budesonido |
| ATE204743T1 (de) | 1991-12-18 | 2001-09-15 | Minnesota Mining & Mfg | Aerosolzusammensetzungen für arzneimittelsuspensionen |
| GB9206989D0 (en) | 1992-03-31 | 1992-05-13 | Glaxo Group Ltd | Chemical compounds |
| US5239993A (en) | 1992-08-26 | 1993-08-31 | Glaxo Inc. | Dosage inhalator providing optimized compound inhalation trajectory |
| AU7545894A (en) | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| US5415162A (en) | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
| EP0747355A4 (de) | 1994-02-10 | 1997-04-09 | Yamanouchi Pharma Co Ltd | Neue carbamate und diese enthaltende arzneimittel |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| RU2126001C1 (ru) * | 1995-01-10 | 1999-02-10 | Самдзин Фармасьютикал Ко., Лтд | Производные пиперазина и фармацевтическая композиция на их основе |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| RO119116B1 (ro) | 1995-04-14 | 2004-04-30 | Glaxo Wellcome Inc. | Inhalator pentru dozarea salmeterolului |
| US6464979B1 (en) * | 1996-09-12 | 2002-10-15 | Aventis Pasteur Limited | Chlamydial vaccines and methods of preparation thereof |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| JP2002506856A (ja) | 1998-03-14 | 2002-03-05 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | フタラジノンpdeiii/iv阻害剤 |
| AU755066B2 (en) | 1998-04-18 | 2002-12-05 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| WO1999064043A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Muscarinic receptor antagonists |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| US6693202B1 (en) * | 1999-02-16 | 2004-02-17 | Theravance, Inc. | Muscarinic receptor antagonists |
| PT1169019E (pt) | 1999-04-14 | 2003-07-31 | Glaxo Group Ltd | Formulacao farmaceutica em aerossol |
| DE19933926A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Pharma | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6510182B1 (en) * | 1999-10-25 | 2003-01-21 | Freesystems Pte. Ltd. | Wireless infrared digital audio system |
| EP1235802B1 (de) | 1999-12-07 | 2005-07-13 | Theravance, Inc. | Carbamat-derivate als muscarin-rezeptor antonisten |
| UA73543C2 (uk) * | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| ATE305468T1 (de) | 2000-12-22 | 2005-10-15 | Almirall Prodesfarma Ag | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten |
| US6656694B2 (en) | 2001-01-11 | 2003-12-02 | Theravance, Inc. | Method for identifying a ligand for a biological substrate |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| AU2002326026B2 (en) | 2001-09-14 | 2005-04-28 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| AU2003258507A1 (en) | 2002-07-30 | 2004-02-23 | Unilever Plc | Abrasive hard surface cleaning compositions |
| UY27927A1 (es) | 2002-08-06 | 2003-12-31 | Glaxo Group Ltd | Antagonistas del receptor muscarínico m3 de acetilcolina |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP4851937B2 (ja) * | 2003-11-21 | 2012-01-11 | セラヴァンス, インコーポレーテッド | β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
| TW200538095A (en) * | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1723112A1 (de) | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Als antagonisten für den muscarinrezeptor geeignete biphenylverbindungen |
| EP1723113A1 (de) * | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen |
| WO2005087737A1 (en) | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| JP2007528416A (ja) | 2004-03-11 | 2007-10-11 | セラヴァンス, インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物 |
| JP2007528412A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス, インコーポレーテッド | ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物 |
| EP1723109A1 (de) | 2004-03-11 | 2006-11-22 | Theravance, Inc. | Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen |
| JP2008537931A (ja) | 2005-03-10 | 2008-10-02 | セラヴァンス, インコーポレーテッド | ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物 |
| TW200714587A (en) | 2005-03-10 | 2007-04-16 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7659403B2 (en) | 2005-03-10 | 2010-02-09 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| EP1866284A1 (de) | 2005-03-10 | 2007-12-19 | Theravance, Inc. | Biphenylverbindungen als muskarinrezeptorantagonisten |
| JP2008533028A (ja) | 2005-03-10 | 2008-08-21 | セラヴァンス, インコーポレーテッド | ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物 |
| TWI372749B (en) | 2005-03-10 | 2012-09-21 | Theravance Inc | Crystalline forms of a biphenyl compound |
| US7728144B2 (en) | 2005-06-13 | 2010-06-01 | Theravance, Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| US20070029346A1 (en) * | 2005-08-03 | 2007-02-08 | Fu-Tian Hung | Pneumatic greaser |
| TW200811105A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| JP2009535462A (ja) * | 2006-04-27 | 2009-10-01 | インテザイン テクノロジーズ, インコーポレイテッド | 化学的に異なる末端基を含むポリ(エチレングリコール) |
| BR112012000890A2 (pt) | 2009-07-15 | 2017-10-31 | Theravance Inc | formas de base livre cristalina de um composto bifenil |
| JP5959117B2 (ja) | 2010-07-13 | 2016-08-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ビフェニル−2−イルカルバミン酸を調製するためのプロセス |
-
2005
- 2005-02-15 TW TW094104354A patent/TWI341836B/zh not_active IP Right Cessation
- 2005-03-10 EP EP08151157A patent/EP1930323B1/de not_active Expired - Lifetime
- 2005-03-10 AT AT08151157T patent/ATE467617T1/de not_active IP Right Cessation
- 2005-03-10 AR ARP050100927A patent/AR048032A1/es active IP Right Grant
- 2005-03-10 MY MYPI20051008A patent/MY144482A/en unknown
- 2005-03-10 RU RU2006135927/04A patent/RU2366656C2/ru active
- 2005-03-10 HR HR20080301T patent/HRP20080301T3/xx unknown
- 2005-03-10 EP EP05730087A patent/EP1723114B1/de not_active Expired - Lifetime
- 2005-03-10 US US11/077,433 patent/US7288657B2/en active Active
- 2005-03-10 CN CN2005800076368A patent/CN1930125B/zh not_active Expired - Lifetime
- 2005-03-10 SI SI200530283T patent/SI1723114T1/sl unknown
- 2005-03-10 PL PL05730087T patent/PL1723114T3/pl unknown
- 2005-03-10 ES ES05730087T patent/ES2306125T3/es not_active Expired - Lifetime
- 2005-03-10 DE DE602005006757T patent/DE602005006757D1/de not_active Expired - Lifetime
- 2005-03-10 CA CA2557479A patent/CA2557479C/en not_active Expired - Lifetime
- 2005-03-10 AU AU2005222411A patent/AU2005222411B2/en not_active Expired
- 2005-03-10 PT PT05730087T patent/PT1723114E/pt unknown
- 2005-03-10 WO PCT/US2005/007988 patent/WO2005087738A1/en not_active Ceased
- 2005-03-10 ES ES08151157T patent/ES2345640T3/es not_active Expired - Lifetime
- 2005-03-10 DE DE602005021258T patent/DE602005021258D1/de not_active Expired - Lifetime
- 2005-03-10 NZ NZ549472A patent/NZ549472A/en not_active IP Right Cessation
- 2005-03-10 AT AT05730087T patent/ATE395335T1/de active
- 2005-03-10 JP JP2007503012A patent/JP4837653B2/ja not_active Expired - Lifetime
- 2005-03-10 DK DK05730087T patent/DK1723114T3/da active
- 2005-03-10 BR BRPI0508622A patent/BRPI0508622B8/pt not_active IP Right Cessation
-
2006
- 2006-08-08 IL IL177359A patent/IL177359A/en active IP Right Grant
- 2006-08-24 ZA ZA200607099A patent/ZA200607099B/xx unknown
- 2006-10-09 NO NO20064579A patent/NO338941B1/no unknown
- 2006-10-10 KR KR1020067021073A patent/KR101174740B1/ko not_active Expired - Lifetime
- 2006-10-11 MA MA29377A patent/MA28524B1/fr unknown
-
2007
- 2007-07-19 US US11/879,835 patent/US7910608B2/en active Active
- 2007-07-19 US US11/880,002 patent/US7550595B2/en not_active Expired - Lifetime
- 2007-07-19 US US11/879,996 patent/US7585879B2/en not_active Expired - Lifetime
- 2007-07-19 US US11/880,007 patent/US7491736B2/en not_active Expired - Lifetime
- 2007-09-05 US US11/899,181 patent/US8017783B2/en active Active
- 2007-10-12 US US11/974,318 patent/US7521041B2/en not_active Expired - Lifetime
-
2008
- 2008-06-19 CY CY20081100652T patent/CY1109015T1/el unknown
-
2009
- 2009-05-08 US US12/437,766 patent/US7803812B2/en not_active Expired - Lifetime
-
2010
- 2010-06-14 US US12/814,629 patent/US8034946B2/en not_active Expired - Lifetime
-
2011
- 2011-02-10 US US13/024,532 patent/US8053448B2/en not_active Expired - Lifetime
- 2011-09-07 US US13/226,677 patent/US8173815B2/en not_active Expired - Lifetime
-
2012
- 2012-04-03 US US13/438,105 patent/US8273894B2/en not_active Expired - Lifetime
- 2012-08-23 US US13/592,713 patent/US8557997B2/en not_active Expired - Lifetime
-
2013
- 2013-09-11 US US14/023,794 patent/US8912334B2/en not_active Expired - Lifetime
-
2014
- 2014-11-12 US US14/539,550 patent/US9283183B2/en not_active Expired - Lifetime
-
2016
- 2016-02-05 US US15/016,528 patent/US9452161B2/en not_active Expired - Lifetime
- 2016-04-28 AR ARP160101213A patent/AR104444A2/es active IP Right Grant
- 2016-08-30 US US15/251,144 patent/US9926272B2/en not_active Expired - Lifetime
-
2018
- 2018-01-22 US US15/876,525 patent/US10106503B2/en not_active Expired - Lifetime
- 2018-09-13 US US16/130,076 patent/US10343995B2/en not_active Expired - Lifetime
-
2019
- 2019-05-23 US US16/420,421 patent/US10570092B2/en not_active Expired - Lifetime
-
2020
- 2020-01-16 US US16/744,565 patent/US11247969B2/en not_active Expired - Lifetime
-
2022
- 2022-01-05 US US17/569,255 patent/US12258316B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE395335T1 (de) | Als muscarinrezeptorantagonisten geeignete biphenylverbindungen | |
| CY2017008I2 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| DK1740177T3 (da) | Antagonister til muskarinfølsomme acetylcholinreceptorer | |
| ATE537151T1 (de) | Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten | |
| DK2089382T3 (da) | Substituerede diazepan-forbindelser som orexin-receptor-antagonister | |
| ATE413400T1 (de) | Cgrp-rezeptorantagonisten | |
| DK1682142T3 (da) | M3-muscarin-acetylcholin-receptor-antagonister | |
| ATE509928T1 (de) | 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten | |
| NL1028624A1 (nl) | Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten. | |
| DK2094709T3 (da) | Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister | |
| DK2009992T3 (da) | Il-8 receptor-antagonister | |
| ATE420088T1 (de) | Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten | |
| ATE545633T1 (de) | Als vasopressinantagonisten geeignete benzazepinderivate | |
| DK1711465T3 (da) | Hydroisoindolin-tachykinikreceptorantagonister | |
| ATE517100T1 (de) | Pyrrolidinarylether als nk3-rezeptorantagonisten | |
| ATE519738T1 (de) | Pyrrolidinarylether als nk3-rezeptorantagonisten | |
| ATE477243T1 (de) | 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten | |
| DK1973886T3 (da) | Prokineticin-1-receptor-antagonister | |
| DE602005009355D1 (de) | Gehinderte himbacinanaloga als thrombinrezeptorantagonisten | |
| ATE429428T1 (de) | Indanderivate als antagonisten des mch-rezeptors | |
| EP1799672A4 (de) | Cgrp-rezeptorantagonisten | |
| EP1812008A4 (de) | Il-8-rezeptorantagonisten | |
| DE602006003666D1 (de) | Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten | |
| DE602006018334D1 (de) | Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten | |
| ATE528291T1 (de) | Cyclopropylderivate als nk3 rezeptor-antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |